Centre for Human Drug Research
↗Leiden, Netherlands
The Centre for Human Drug Research (CHDR) is an independent, non-profit foundation and full-service contract research organization (CRO) based in Leiden, Netherlands. Established in 1987, it specializes in early-phase clinical drug research, conducting studies in both healthy volunteers and small patient cohorts to provide high-quality clinical pharmacology data to the pharmaceutical and biotech industries.
CHDR is known for its academic collaborations, state-of-the-art clinical research facilities (including a dedicated Phase 1 unit), and the development of innovative research tools and biomarkers, such as the NeuroCart and PainCart systems. The organization serves as a 'one-stop-shop' for early-phase programs, offering services ranging from study design and regulatory support to clinical execution, data management, and pharmacometrics.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Founded:1987
Ownership:nonprofit
Status:operating
FUNDING
Investors:Europa
PIPELINE
Stage:Discovery
Lead Drug Stage:N/A (CRO)
Modalities:Small molecule, Biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Academic centers and university hospitals in the Netherlands, TechMed Centre (University of Twente)
COMPETITION
Position:Niche Player
Competitors:Vasta Global, S-Cubed, Blue Matter Consulting
LEADERSHIP
Key Executives:
Adam Cohen - CEO
Scientific Founders:Douwe Breimer
LINKS
Website:chdr.nl
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Centre for Human Drug Research and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Centre for Human Drug Research. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.